Search results for "Acute [MeSH]"

showing 10 items of 350 documents

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable resi…

2020

In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81 center dot 5% an…

OncologyAdultMalemedicine.medical_specialtyNPM1Neoplasm ResidualAdolescentDiseasestem cell transplantationDisease-Free Survival03 medical and health sciencesEuropean LeukemiaNet0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineHumansacute myeloid leukaemiamolecular analysisCumulative incidenceAgedbusiness.industryInduction chemotherapyMyeloid leukemiaNuclear ProteinsHematologyInduction ChemotherapyMiddle AgedNeoplasm ProteinsTransplantationEuropeSurvival RateHaematopoiesisLeukemia Myeloid Acute030220 oncology & carcinogenesisleukaemiaMutationFemalebusinessNucleophosmin030215 immunologyBritish journal of haematologyReferences
researchProduct

Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute …

1993

Aggressive chemotherapy of advanced myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) evolving from MDS, subacute AML and secondary AML has usually been associated with low complete remission (CR) rates, a high incidence of early death, and low disease-free survival. We therefore have initiated a phase-III trial of aggressive chemotherapy consisting of idarubicin, cytosine arabinoside, and VP-16 to improve the CR rate. Each chemotherapy cycle is followed by G-CSF to accelerate neutrophil recovery and to reduce the incidence of infections. Until now, 19 patients with high-risk AML have been entered. The CR rate is 47%, with only one death during induction. Patients achieving CR ar…

OncologyAdultMalemedicine.medical_specialtymedicine.medical_treatmentMaintenance therapyhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineSecondary Acute Myeloid LeukemiaIdarubicinHumansEtoposideAgedEtoposideChemotherapybusiness.industryRemission InductionCytarabineMyeloid leukemiaHematologyGeneral MedicineMiddle AgedGranulocyte colony-stimulating factorLeukemia Myeloid AcuteMyelodysplastic SyndromesImmunologyCytarabineInterleukin-2FemalebusinessIdarubicinmedicine.drugAnnals of hematology
researchProduct

Tumorigenic and metastatic activity of human thyroid cancer stem cells

2010

Abstract Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDHhigh) activity and unlimited replication potential. ALDHhigh cells can be expanded indefinitely in vitro as tumor spheres, which retain the tumorigenic potential upon delivery in immunocompromised mice. Orthotopic injection of minute numbers of thyroid cancer stem cells recapitulates the behavior of the parental tumor, including the aggressive metastatic features of undifferentiated thyroid carcinomas, which are sustained by…

OncologyMaleCancer ResearchLung NeoplasmsPapillaryNudeMessengerThyroid GlandFluorescent Antibody TechniqueTYROSINE KINASEMice SCIDCell TransformationImmunoenzyme TechniquesMiceMice Inbred NODCell MovementAdenocarcinoma FollicularThyroid cancerRADIOACTIVE IODINETumor Stem Cell AssayEPITHELIAL-MESENCHYMAL TRANSITION; ALDEHYDE DEHYDROGENASE-ACTIVITY; ACUTE MYELOID-LEUKEMIA; RADIOACTIVE IODINE; TYROSINE KINASE; LUNG-CANCER; CARCINOMA; RECEPTOR; GROWTH; DIFFERENTIATIONBlottingReverse Transcriptase Polymerase Chain ReactionThyroidMiddle AgedProto-Oncogene Proteins c-metFlow CytometryEPITHELIAL-MESENCHYMAL TRANSITIONmedicine.anatomical_structureCell Transformation NeoplasticDIFFERENTIATIONOncologyNeoplastic Stem CellsAdenocarcinomaGROWTHFemaleStem cellWesternAdultmedicine.medical_specialtyBlotting WesternMice NudeACUTE MYELOID-LEUKEMIABiologyAdenocarcinomaSCIDALDEHYDE DEHYDROGENASE-ACTIVITYThyroid carcinomaYoung AdultLUNG-CANCERAdenocarcinoma Follicular; Adult; Aged; Aldehyde Dehydrogenase; Animals; Blotting Western; Carcinoma; Carcinoma Papillary; Case-Control Studies; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Transformation Neoplastic; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice Inbred NOD; Mice Nude; Mice SCID; Middle Aged; Neoplasm Invasiveness; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA Messenger; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Gland; Thyroid Neoplasms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays; Young Adult; Cancer Research; OncologyCancer stem cellSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineCell AdhesionAnimalsHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsALDH Human Thyroid Cancer Stem CellsAgedCell ProliferationNeoplasticRECEPTORCarcinomaFollicularTumor Stem Cell AssayCancerAldehyde Dehydrogenasemedicine.diseaseXenograft Model Antitumor AssaysCarcinoma PapillaryCase-Control StudiesInbred NODRNAProto-Oncogene Proteins c-akt
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

Effect of Treatment with rhGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes

1990

Treatment of patients having myelodysplastic a syndromes (MDS) with approaches such as differentiation induction, single cytostatic agents or supportive care only has, up to now, been rather unsuccessful. Aggressive chemotherapy followed by bone marrow transplantation is only suitable for a very small proportion of patients. Thus, there is a need for new therapeutic alternatives.

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryCellular differentiationmedicine.medical_treatmentMyelodysplastic syndromesmedicine.diseaseLeukemiaGranulocyte macrophage colony-stimulating factorCytokineInternal medicinePrecursor cellImmunologyCytarabineMedicinebusinessmedicine.drug
researchProduct

GM-CSF in a Double-Blind Randomized Placebo-Controlled Trial in Therapy of Adult Patients with De Novo Acute Myeloid Leukemia

1994

Despite the fact that 60%–70% of patients with de novo acute myeloblastic leukemia (AML) achieve a complete remission (CR) of the disease only about 20%–30% of the patients remain in long term remission and are probably cured [1,2]. These rather disappointing long-term results argue in favor of an even more intensive induction and post-remission therapy. This intention is, however, at time limited by therapy associated toxicity. Especially haematotoxicity seems to be the limiting factor in that patients with profound neutropenia are at high risk of developing fatal infectious complications [3]. In this context haematopoietic growth factors, such as granulocyte-macrophage colony-stimulating …

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryPlacebo-controlled studyMyeloid leukemiaNeutropeniamedicine.diseaseGranulocyte colony-stimulating factorHaematopoiesisPharmacotherapyInternal medicineImmunologymedicineCytarabinebusinessmedicine.drug
researchProduct

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Mea…

2018

Abstract Introduction Patients diagnosed with AML with NPM1mutation (NPM1mut AML) included in the European LeukemiaNet favorable genetic risk category (ELNfav, i.e., without FLT3-ITD or with a low allelic burden FLT3-ITD comutation [FLT3-ITD/FLT3wt <0.5; FLT3-ITDLOW]) do not benefit from an allogeneic stem cell transplantation (alloSCT) in first complete remission (CR1). However, a significant proportion of these patients fail to frontline chemotherapy and require salvage therapy. Persistence or detection of MRD after post-CR treatment is associated with a high relapse risk and worse prognosis. With this background, the cooperative group CETLAM proposed an early therapeutic intervention …

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industrymedicine.medical_treatmentImmunologySalvage therapyCell BiologyHematologyDiseasemedicine.diseaseDebulkingBiochemistryChemotherapy regimenLeukemiaInternal medicinemedicineCytarabinebusinessNeoadjuvant therapymedicine.drugBlood
researchProduct

Wet BNP, fluid and hemodynamic status at discharge in Acute Heart Failure

2010

We comment the noteworthy results of Pimenta et al. concerning the significance of discharge BNP levels in acute HF patients. The innovation of Pimento's study is the systematic research of the potential relationship between BNP and clinical and hemodynamic parameters. We focused the attention on the importance of wet "BNP" in managing HF and its ability to reflect congestion and multiple underlying patho-physiological disturbances. The first observation, regarding the statistical order, underlines the importance of renal insufficiency at discharge in genesis of higher BNP levels. Secondly, we note that the relationship between natriuretic peptides and the non-invasive measurement of the fl…

Oncotic pressuremedicine.medical_specialtySettore MED/09 - Medicina InternaHeart diseasebusiness.industryHemodynamicsPlasma levelsmedicine.diseaseBrain natriuretic peptideSurgeryHeart failureInternal medicineAcute Heart failure Brain natriuretic peptideAmbulatoryCardiologyMedicineCardiology and Cardiovascular MedicinebusinessKidney diseaseInternational Journal of Cardiology
researchProduct

Lights and shadows of cardiac magnetic resonance imaging in acute myocarditis

2016

Cardiac magnetic resonance (CMR) is considered a primary tool for the diagnosis of acute myocarditis, due to its unique potential for non-invasive identification of the various hallmarks of the inflammatory response, with relevant impact on patient management and prognosis. Nonetheless, a marked variation in sensitivity and negative predictive value has been reported in the literature, reflecting the intrinsic drawbacks of current diagnostic criteria, which are based mainly on the use of conventional CMR pulse sequences. As a consequence, a negative exam cannot reliably exclude the diagnosis, especially in patients who do not present an infarct-like onset of disease. The introduction of new…

Opinionmedicine.medical_specialtyacute myocarditis; cardiac magnetic resonance; Lake Louise criteria; T1 mappingDisease030204 cardiovascular system & hematologycardiac magnetic resonance030218 nuclear medicine & medical imaging03 medical and health sciencesacute myocarditis0302 clinical medicineCardiac magnetic resonance imagingNuclear Medicine and ImagingAcute myocarditimedicineRadiology Nuclear Medicine and imagingIn patientSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIANeuroradiologymedicine.diagnostic_testbusiness.industryInterventional radiologyT1 mappingAcute myocarditis; Cardiac magnetic resonance; Lake Louise criteria; T1 mapping; Radiology Nuclear Medicine and ImagingAcute myocarditisLake Louise criteriacardiovascular systemDiffuse diseaseRadiologyRadiologyCardiac magnetic resonancebusinessInsights into Imaging
researchProduct

Rizatriptan in the treatment of migraine.

2006

Migraine is a common, disabling disorder associated with considerable personal and societal burden. Current guidelines recommend triptans for the acute treatment of migraine unlikely to respond to less effective therapies. Rizatriptan is a second-generation triptan available in tablet or orally disintegrating tablet (wafer) formulations that offers several advantages over other members of its class. Rizatriptan is rapidly absorbed from the gastrointestinal tract and achieves maximum plasma concentrations more quickly than other triptans, providing rapid pain relief. Clinical trials have shown that rizatriptan is at least as effective or superior to other oral migraine-specific agents in the…

Orally disintegrating tabletmedicine.medical_specialtybusiness.industryrizatriptanPain reliefTriptansmedicine.diseaseExpert OpinionRizatriptantriptansacute migraineClinical trialPsychiatry and Mental healthserotonin receptor agonistsMigraineTolerabilityAnesthesiaInternal medicinePlasma concentrationmedicinebusinessBiological Psychiatrymedicine.drugNeuropsychiatric disease and treatment
researchProduct